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1. LANTHANIDE-BASED LUMINESCENT PROBES: WHY?
1.1. Basic Properties of Lanthanide Trivalent Ions
The lanthanides, or 4f elements, which extend from lanthanum (atomic 
number 57) through lutetium (71) form essentially trivalent LnIII ions 
in aqueous solution with an electronic structure consisting of a xenon 
core and 4f valence electrons, [Xe]4fn. That is, the valence electrons are 
shielded from external interactions, henceforth, the characteristic chemi-
cal, spectroscopic and magnetic properties of these ions (Table 1). The 
series is termed rare earths when scandium and yttrium are added to it. 
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Chemically, they are hard cations, binding preferentially oxygen and nitro-
gen. Their ionic radii are quite comparable to those of calcium and zinc. 
Moreover, they display Lewis acid properties which make them useful in 
the hydrolytic cleavage of phosphor-diester bonds of DNA which, other-
wise, is extremely resistant to hydrolysis; cleavage of DNA is an essential 
step in developing gene therapy.
Another consequence of the shielding of the 4f orbitals is that the 
selection rules forbidding f-f transitions are only weakly relaxed and these 
transitions are faint and keep their atomic nature, i.e., they appear as sharp 
and weak lines, the energy of which is not much influenced by the sur-
roundings of the metal ion, except for the crystal-field induced fine struc-
ture. This apparent disadvantage may be turned into a serious asset since 
these lines are easily recognizable and very useful for the development 
of valuable luminescent probes with wide potential applications, ranging 
from solid state physics to medical diagnosis. For the same reasons, mag-
netic properties are not much influenced by the nature of the inner coor-
dination sphere and remain essentially those of the free ions; magnetic 
interactions between 4f and 3d or 4f ions occur only when the metal-metal 
distance is short (smaller than 4 Å) and are faint. Several applications 
take advantage of the large paramagnetic susceptibility exhibited by many 
LnIII ions. For instance, ErIII is useful in the separation and isolation of 
particles (e.g., bacterial or eukaryotic cells), and GdIII is the core constitu-
ent of several contrasting agents for the enhancement of medical images 
recorded by magnetic resonance [1].
Luminescence has played an essential role in the discovery of the rare-
earth elements and in their early uses, particularly as inorganic phosphors. 
The first report on the lanthanide-centered luminescence of a coordination 
compound was published in 1942 by Weissman [2]. Using the sun as a 
source of light, Weissman noted that absorption of radiation with wave-
lengths in the range 320 to 440 nm by the organic part of several EuIII 
complexes resulted in the characteristic line luminescence from the f-f 
transitions of trivalent europium. Studying several anionic chelating agents 
such as β-diketonates, benzoates, salicylates or picrates, he observed that 
the efficiency of excitation varies greatly with the nature of the compounds, 
as well as with the temperature and the solvent, and speculated that in 
some cases a quantum yield of unity was obtained at low temperature.
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TABLE 1
Basic properties of trivalent rare earth ions and of CaII: electronic structure, 
intrinsic color (all colors mentioned are pale), magnetic moment in Bohr mag-
netons, ionic radii for coordination numbers 9 and 12, and hydration enthalpy at 
298 K (kJmol–1). Data are taken from [3]
Ion El. Struct. Color μ(B.M.) ri(9)/Å ri(12)/Å −ΔHh0
Ca [Ar] colorless  0 1.18 n.a. 1585
Sc [Ar] colorless  0 0.93 1.06 3884b)
Y [Kr] colorless  0 1.08 1.22 3640
La [Xe] colorless  0 1.22 1.36 3326
Ce [Xe]4f1 colorless  2.56 1.20 1.34 3380
Pr [Xe]4f2 green  3.62 1.18 1.32 3421
Nd [Xe]4f3 violet  3.68 1.16 1.30 3454
Pm [Xe]4f4 rose  2.83 1.14 1.28 3482
Sm [Xe]4f5 cream  1.65 1.13 1.27 3512
Eu [Xe]4f6 pale pink  3.51 1.12 1.25 3538
Gd [Xe]4f7 colorless  7.94 1.11 1.24 3567
Tb [Xe]4f8 colorless  9.7 1.10 1.23 3600
Dy [Xe]4f9 cream  10.6 1.08 1.22 3634
Ho [Xe]4f10 yellow  10.6 1.07 1.21 3663
Er [Xe]4f11 pink  9.6 1.06 1.19 3692
Tm [Xe]4f12 green  7.6 1.05 1.18 3717
Yb [Xe]4f13 colorless  4.5 1.04 1.17 3740
Lu [Xe]4f14 colorless  0 1.03 1.16 3759
The intermolecular energy transfer process between an organic ligand and
a luminescent metal ion is presently designated as the “antenna effect”. 
The discovery stirred interest but no immediate application was found and, 
moreover, coordination chemistry of the LnIII ions did not develop much 
until the 1960’s when it was finally recognized that these ions usually 
display a large coordination number [3,4], which inevitably influences the 
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design of adequate receptors. The excited states of luminescent LnIII ions 
are populated by a fast intramolecular energy transfer process from a triplet 
state of the ligand (itself populated from the singlet state by intersystem 
crossing), as demonstrated for the first time by Crosby et al. [5]. Estimates 
for the transfer rate range between 106 to 109 s–1.
1.2. Lanthanide Luminescent Probes in Biological Systems
Luminescence is a highly sensitive analytical method since nowadays 
single molecule detection is becoming common and henceforth, its inter-
est for medical analysis and diagnosis. However, biological material is 
highly complex and usually bears numerous fluorescent groups. There-
fore, luminescent stains based on organic dye molecules, although highly 
sensitive, are not completely adequate in view of the difficulty in separat-
ing the fluorescence of the stain from that of the sample. On the other 
hand, lanthanide ions are ideal luminescent probes for biological systems 
because their line-like emission bands are easily recognizable, well sepa-
rated from the broad band fluorescence emission from organic moieties 
and, moreover, light emission by these metal ions is a phosphorescence 
process. The excited states are therefore long-lived, allowing, in addition, 
time-resolved separation of the LnIII ion phosphorescence from the fluo-
rescence of the biological sample. As a consequence, the luminescent LnIII 
ions seem to be ideally suited for becoming widely used probes in biologi-
cal systems. There are however two problems to overcome. The first one 
is related to the need of going through a sensitisation process of the metal 
ion luminescence via the antenna effect (vide supra). Secondly, LnIII ions 
are toxic [6]. There are known to have bacteriological effects, to easily 
replace calcium and zinc (and possibly other biologically relevant metal 
ions), and to kill cells. Although the latter property may be turned into an 
advantage, for instance for curing cancer, it is not welcome for diagnos-
tic tools. The LnIII ions have therefore to be inserted into highly stable 
molecular edifices, both from the thermodynamic and kinetic viewpoints. 
This represents a challenging task for the synthetic chemists, which now 
begins to find appealing solutions.
Historically, the first application of luminescent LnIII ions for the anal-
ysis of biological systems has been the investigation of metal ion sites in 
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proteins, mainly calcium-binding proteins. In these studies, EuIII and TbIII 
act as replacement probes and the number of metal ion sites, their chemi-
cal composition (especially with respect to the number of coordinated 
water molecules), as well as their mutual distances have been determined 
with good accuracy. This type of analysis continues to attract interest, as 
described in recent review articles [7,8].
A big stimulus arose in the mid 1980’s when a small Finnish 
company, Wallac Oy from Turku, marketed bioassays based on time-
resolved luminescence of EuIII [9]. These fluoroimmunoassays (FIA) 
rely on antibodies labelled with lanthanide chelates which specifically 
react with the targeted antigens. Since then, many research groups have 
been developing carefully engineered organic molecules able to encap-
sulate the LnIII ions and to enhance their luminescent properties. This 
growing interest for molecular devices built from organic molecules is 
also motivated by the development of other recent biomedical applica-
tions such as DNA and RNA labelling, nucleic acid hybridization assays 
[10], and by the design of luminescent responsive systems for in vitro 
trace analysis [11].
In the following sections, the discussion focuses on lanthanide-con-
taining diagnostic tools for biology and medicine, as well as on some 
potential therapeutical applications. It is not intended to present a compre-
hensive review of these fields but, rather, to exemplify some of the main 
applications.
2. DESIGNING A LANTHANIDE-BASED
 LUMINESCENT PROBE
2.1. Photophysical Aspects
Which ions are of interest in the reviewed field? In fact, most LnIII ions 
are luminescent, but medical applications require the use of organic com-
plexes in aqueous solution and at physiological pH of 7.4, which severely 
limits the choice of potentially interesting ions. Indeed, the emission 
intensity is qualitatively inversely proportional to the energy gap between 
the lowest lying excited (emissive) state of the metal ion and its ground
manifold. Emission from higher excited states is rarely seen in solution. 
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FIG. 1. Partial energy diagrams of some luminescent LnIII ions. Luminescent 
states are indicated by down-pointing arrows.
When the gap is small, it can be easily bridged by nonradiative processes 
involving vibrational levels, which are numerous in organic complexes. 
Taking this requirement into account, the best ions are therefore EuIII, 
GdIII, and TbIII, with energy gaps around 12150, 32000, and 14800 cm–1, 
respectively (FIG. 1).
However, GdIII emits in the UV and is not much useful since its lumi-
nescence will interfere with either luminescence or absorption processes 
in the organic part of the complex molecule. Developments of dual fluoro-
immunoassays has also stirred interest for the luminescence of SmIII (gap 
7400 cm–1) and DyIII (7850 cm–1), as well as, more recently, the advent 
of chiral luminescent probes emitting in the far infrared has stimulated 
attention to NdIII (5500 cm–1) and YbIII (10400 cm–1), despite their very 
low quantum yields.
As noted above, f-f transitions are very weak, so that direct excitation 
of the LnIII ions rarely yields highly luminescent materials. Indirect excita-
tion (called sensitization or antenna effect) has to be used and proceeds in 
three steps. First, light is absorbed by the immediate environment of the 
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LnIII ion through the attached organic ligands (chromophores). Energy is 
then transferred onto the metal ion mainly through the ligand triplet state 
and, fi nally, the metal ion emits light. This process results in light-convert-
ing devices since usually UV or blue light is absorbed while green (Tb), 
yellow (Dy), orange (Sm), red (Eu) or near IR (Nd, Yb) light is given off. 
A simplifi ed scheme of these energy transfer processes is given in Figure 2. 
As seen from this schematic diagram, more than ten energy migration paths 
are possible, in general, each characterized by a rate constant. For EuIII 
and other easily reducible lanthanide ions, metal-to-ligand charge transfer 
states must be considered, especially if they lie below 25,000 cm–1 since 
they deactivate the metal excited state, which adds more energy migra-
tion paths to the scheme. Moreover, the picture is not exhaustive, since we 
have not taken into account intermolecular processes which may gain in 
importance either in solids where LnIII ions lie at relatively short distances 
so that energy can migrate from one metallic site to the other, or in solution 
where collisions with other molecules may result either in benefi cial energy 
transfers or in the deactivation of the metal ion excited state. Polymeric 
structures containing both luminescent and non-luminescent LnIII ions may 
FIG. 2. Simplifi ed diagram showing the energy migration paths in a LnIII complex 
(1S = singlet state, 3T = triplet state, F = fl uorescence, P = phosphorescence, isc 
= intersystem crossing, nr = nonradiative, ic = internal conversion, et = energy 
transfer, back = back transfer, T = temperature-dependent, el = electronic, vibr = 
vibrational.
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also lead to enhanced luminescent properties through energy transfer from 
the non-luminescent centers onto the luminescent ones.
2.1.1. Optimising Energy Transfer Processes
In absence of good predictive theoretical models, experimentalists have 
to rely on rules of thumb and several of them have been established for 
given series of EuIII and TbIII compounds. Two main processes have to be 
optimized: the intersystem crossing (kisc) and the 3ππ*-to-metal energy 
transfer (ket). Consequently, energy losses have to be avoided at all stages: 
light emission or non-radiative de-excitation from the ligand (kF, knrF , kP, 
and knrP ), as well as non-radiative de-excitation of the metal ion lumines-
cent state (knri ).
From organic photochemistry data, it is known that efficient isc takes 
place when ΔE(1ππ*-3ππ*) is around 5000 cm–1.
With respect to the triplet-to-metal ion transfer, two series of com-
pounds have been studied in detail and are often referred to: (i) EuIII and 
TbIII polyaminocarboxylates for which the quantum yield upon ligand 
excitation becomes sizeable when ΔE(3ππ*-5DJ) > 2000 cm–1 [12]. When 
this gap is smaller, energy back transfer can occur (kback), and (ii) com-
plexes with triphenylene-substituted calix[4]arenes for which the ideal 
ΔE(3ππ*-5DJ) gap is around 3500 cm–1 [13]. Note that E(3ππ*) refers to 
the zero-phonon transition.
These considerations are somewhat oversimplified. The mechanism of 
the ligand-to-metal energy transfer has often a dipole-dipole nature. The 
overlap integral J between the emission spectrum of the donor (3ππ*) state 
and the absorption spectrum of the acceptor state has also to be taken into 
consideration. This quantity may vary considerably depending upon the 
width of the 3ππ* emission spectrum and, also, upon the orientation of the 
chromophore with respect to the LnIII ion. Moreover, the distance between 
the chromophore and the LnIII ion is crucial since the dipole-dipole trans-
fer fades off as (rDA)–6.
The overall luminescence quantum yield of the metal-centered lumi-
nescence upon excitation through the ligand states can be expressed as:
Qtot = ηisc • ηe • QLn (1)
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where ηisc is the yield of the intersystem crossing to the triplet state, ηet the 
efficiency of the ligand-to-LnIII energy transfer; QLn is expressed as:
(2)
where k’s are deactivation rate constants (radiative and non-radiative) and 
τ’s are lifetimes of the metal excited level. In the particular case of EuIII, 
the radiative lifetime can be estimated by:
(3)
n is the refractive index of the solution, Itot the total integrated emission 
intensity, and IMD the integrated intensity of the magnetic dipole transition 
5D0→7F1. Therefore, a measurement of QLn, τobs and the entire emission 
spectrum (580-820 nm, 5D0→7FJ transitions with J = 0-6) allows one to 
determine ηet. 
2.1.2. Minimizing Non-radiative Processes
Two types of processes intervene, vibrational and electronic, and both are 
temperature-dependent. The most effective vibrations for deactivating an 
excited state are those with high energy, especially when one donor atom 
involved in the vibration is directly connected to the metal ion via a chemical 
bond. The de-excitation effectiveness is inversely proportional to the number 
of vibrational quanta required to match the gap between the lowest sub-level 
of the excited state and the highest sublevel of the ground state. Phonon-
assisted deactivation has been taken advantage of to determine the number 
of water molecules coordinated onto SmIII, EuIII, TbIII, DyIII, and YbIII ions 
by measuring the lifetime τ of the excited levels both in water and deuterated 
water (for a summary, see [14]). Assuming that nonradiative processes other 
than the quenching by high energy vibrations are the same in both cases, and 
that water exchange is fast, the difference in the measured rate constants will 
be proportional to the number of coordinated OH oscillators, that is to the 
number q of coordinated water molecules:
Δkobs = kobs(H2O) – kobs(D2O) = τ–1(H2O) – τ–1(D2O) ∝ q (4)
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Calibrating the relationship with compounds for which the number 
of coordinated water molecules is known (for instance by X-ray 
crystallography, or by NMR) allows one to determine the proportionality 
constant. The main hypothesis made is that each bound OH oscillator 
contributes equally to the quenching process, which in turn implies that 
the Ln-OH distance is the same in compounds in which both only a few or 
many water molecules are bound into the first coordination sphere of the 
metal ion. The assumption seems to hold fairly well and accuracy of about 
± 10% on the number of water molecules can be reached. The accuracy 
depends on the number of corrective factors taken into consideration (for 
instance second sphere interactions) and on the quality of the calibration 
for a given series of compounds.
Electronic deactivation processes are also very important. When a 
molecule is excited by absorption of light, its electron donor or electron 
acceptor properties are modified. For instance, it may become a more 
powerful electron donor. Consequently, an electron transfer, not feasible 
in the ground state, may occur upon photo-excitation. The phenomenon 
is known as photo-induced electron transfer (PET). Although it often 
prevents the design of highly luminescent stains, it may prove useful in 
the planning of analytical methods or in the development of signalling 
processes and molecular logic gates [15]. When such PET processes 
involve the direct reduction (or oxidation) of a metal ion, one often speaks 
of ligand-to-metal charge transfer (LMCT), or of metal-to-ligand charge 
transfer (MLCT). In view of the redox potentials of the LnIII ions, only 
SmIII, EuIII, and YbIII are amenable to reductive LMCT processes, while 
MLCT’s can essentially occur with CeIII and TbIII. In any case, these 
processes, which are usually very fast, efficiently compete with the LnIII* 
deactivation and quench the luminescence.
2.1.3. Energy Back Transfer
When both the excited metal ion and the ligand triplet levels lie close 
in energy, energy from the former can flow back onto the ligand. This 
process is often assisted by vibrations and the temperature dependence of 
the lifetime can be described by an Arrhenius-type equation:
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(5)
where τ is the actual lifetime, τ0 the lifetime in absence of back transfer 
(frequently taken as the lifetime at very low temperature), while EA is the 
activation energy of the process which often matches a vibration of the 
molecule under study. 
2.2. Chemical Aspects
The ionic radii of LnIII ions sustain a rather smooth decline (disregarding 
small, second order effects) with increasing atomic number (Table 1). As 
the nucleus charge increases, it exerts a greater electrostatic attraction 
over the 4f electrons, henceforth the so-called “lanthanide contraction”. 
It is noteworthy that the ionic radii strongly depend upon the coordina-
tion number (Table 1), which makes the LnIII ions highly adaptable to 
many coordination environments. Indeed, the difference in ionic radius 
between coordination numbers 6 and 12 amounts to 0.3 Å while it is only 
0.16 Å between La and Lu and ≈ 0.015 Å between two consecutive ions. 
Moreover, the spherical trivalent lanthanides are labile and stereochemi-
cally versatile metal ions, so that a rational control of their coordination 
sphere entirely relies on conformational restriction of the receptors. This 
poses a real challenge to synthetic chemists if a given LnIII ion were to 
be introduced specifically into a functional edifice.
2.2.1. Thermodynamic Considerations
From the thermodynamic viewpoint, in aqueous solution, the enthalpy and 
entropy changes on formation of complexes is usually more influenced by 
changes in the hydration of cations and ligands (especially if the latter are 
anionic) than by the cation-ligand interaction itself. Complexation always 
results in a decrease in the hydration of the ions and of the ligands, which 
provides a positive entropy change, reflecting the increase in randomness 
of the system. In the particular case of multidentate ligands, this results in 
a large chelate effect. The more the ligand is pre-organized, respectively 
pre-disposed, the larger the chelate effect (in the case of macrocyclic 
ligands, one speaks of “macrocyclic effect”). The entire complexation 
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process between a Ln3+ ion and a charged ligand Ln– may be viewed as 






Therefore, the total variation of free Gibbs energy for the reaction:
 (8)
can be expressed at constant pressure and temperature as: 
                (9)
Usually, there is a compensation effect, that is ΔHd ≈ –TΔSd so that ΔGd 
≈ 0. Experimentally, ΔSr is positive (especially for macrocyclic ligands), 
and so is very often ΔHr (which means that usually, the Ln-L bonds are 
weaker than the Ln-OH2 ones) so that complexation reactions in water are 
entropy driven and, moreover, a linear relationship between ΔHr and ΔSr 
holds for the Ln(III) series of cations. One has, however, to be cautious 
when this approach is applied to polydentate ligands. The thermodynamic 
parameters may also reflect other factors such as the formation of stable 
5-membered chelate rings. When another solvent is considered, the solva-
tion enthalpy is much smaller than in water and the above considerations 
may no more hold.
2.2.2. Kinetics
Trivalent lanthanide ions are known as being kinetically very labile, with 
water exchange rates in the range 107-109 s-1 Complexation reactions with 
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non-cyclic, simple, ligands or self-assembly processes are also quite fast. In 
general, the reaction sequence fits within the Eigen-Tamm mechanism:
 (10)
The first step is diffusion-controlled and is the fastest step in the com-
plexation process. It leads to the formation of an outer-sphere complex 
which, in a subsequent stage yields the inner-sphere complex. The overall 
rate of complex formation with simple ligands (such as SO4
2–) may be as 
fast as the water exchange processes. For multidentate ligands, the rate 
determining step is usually the ring-closure step, and the overall forma-
tion constant becomes small: for instance, the pseudo first-order rate 
constant for the formation of the lutetium complex with dtpa (a branched 
polyaminocarboxylate, diethylenetriaminepentaacetic acid) amounts to 
4.6 mn–1 at pH 7.8 and 298 K. For macrocyclic ligands, and in non-aque-
ous solvents, the situation may be dramatically different. For instance, 
the pseudo first-order rate constant at pH 7.8 and 298 K for the formation 
of the Lu(III) complex with the tetra-anionic macrocyclic dota ligand 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) amounts to 
only 6.3 × 10–3 mn–1, which is almost three orders of magnitude smaller 
than with dtpa and corresponds to a half-life of 110 min. It therefore takes 
several days to reach thermodynamic equilibrium under these experimen-
tal conditions. Since the metal ion competes with the proton, the reaction 
rate is lowered when the pH is decreased. Longer spans of time are needed 
to reach equilibrium with cryptands (up to several weeks).
2.2.3. Synthetic Strategies
In our case, the receptor must match the coordination number require-
ment of the LnIII ion (usually 8-10) and provide strong metal-ligand interac-
tions so that the resulting edifice does not dissociate in solution. In addition, 
photophysical requirements discussed above must be satisfied, particularly 
with respect to the antenna effect and the minimization of non-radiative de-
excitation. In view of the difficulty in meeting all these constraints, several 
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different strategies have been tested and used. One is based on the lock 
and key principle and uses relatively rigid macrocyclic or macropolycyclic 
ligands (organized receptors). The fine-tuning of their cavity size is however 
very difficult to achieve, so that receptors based on the induced fit principle 
are more popular. These receptors are pre-disposed, that is they build a 
cavity upon reacting with the metal ion. Several classes of molecules can be 
used, large flexible macrocycles, macrocycles bearing functionalized pen-
dant arms, or multidentate podands. Finally, self-assembly processes can 
also be quite successful in encapsulating a metal ion into a complex edifice. 
These aspects are summarized in several review articles [4,16-18].
2.3. Biochemical Aspects
Finally, since the luminescent probe has to be attached onto a biological 
molecule, it has to bear adequate coupling groups, henceforth, the 
designation of “bifunctional” chelates. There are many different methods 
to label biological material and a good insight into the problem is given 
by the review article of Mayer and Neuenhofer [19]. As far as luminescent 
lanthanide stains are concerned, one relatively simple group to introduce 
into bifunctional labels is isothiocyanatophenyl, which was used in the early 
times of heterogeneous immunoassays (1-3, Figure 3). Sometimes, however, 
this group is not easy to graft onto a receptor; for instance, Rodriguez-Ubis et 
al. report that 4 requires a tedious synthetic preparation and is very difficult 
to purify [20]. Other obvious groups could be carboxylic acids (see 7, Figure 
3) or primary amines at the end of a relatively long aliphatic chain (to 
prevent direct interaction between the lanthanide chelate and the biological 
material). Good success has been met by chlorosulfonyl groups grafted on 
relatively complex chromophores (see 5 and 6 on Figure 3). When it comes 
to intercalate a reporter group into DNA strands, methylphenanthridine 
groups (8, Figure 3) are very effective.
The following sections will essentially focus on applications of 
lanthanide luminescence in medical diagnosis and therapy. Another 
aspect of interest is the determination of intramolecular distances in 
macromolecules, particularly proteins, through resonant energy transfer. In 
this method, one analyses how the lifetime τ and emission intensity I of a 
reporter luminescent molecule (the donor) are influenced by the presence of 
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an energy acceptor; if one assumes a dipole-dipole (Förster) mechanism for 
the energy transfer, the distance RDA is given by the following equation:
 (11)
in which indices 0 refer to the situation where no energy transfer occurs. R0 
is the critical distance for 50% transfer; it depends on an orientation factor 
and on the overlap integral between the emission spectrum of the donor 
and the absorption spectrum of the acceptor [21]. Lanthanide-containing 
luminescent probes have defi nite advantages over organic molecules, 
especially because their long lifetime allows random orientation of the 
donor and acceptor during the energy transfer process, in addition to 
the advantages mentioned earlier (line-like emission lines). Distances 
between 20 and 100 Å can be conveniently determined by this lumines-
cent resonant energy transfer (LRET) method [22]. Many studies use 
thiol-reactive chelators to bind a LnIII ion at an engineered Cys residue in 
the macromolecule. An alternative approach has recently been proposed 
in which an EF-hand motif comprised of two α-helices connected by a 
loop containing 12 amino acids is connected to the macromolecule. Six of 
the latter build a metal-binding site with high selectivity for CaII. Because 
of the well-known similarities between the chemical properties of CaII 
and LnIII, the trivalent ions are also bound selectively. This new approach 
has been successfully tested for the estimation of distances in a polytopic 
membrane transport protein, LacY [23].
To illustrate further the problematic of labelling biological 
material, we refer to another recent article describing the binding of 
a terbium dota complex to an antibody, 2D12.5 [24]. Antibodies that 
bind selectively lanthanide chelates under physiological conditions 
can fi nd welcome applications in diagnosis (e.g. immunoassays) and 
therapy. In this work, dota has been derivatized in two ways (Figure 
4) by the addition of (S)-2-(4-(2-bromo)-acetamido)-benzyl (BAD) 
and (S)-2-(4-nitrobenzyl) (NBD) on one of the ring methylene groups. 
The complex between YIII and BAD was linked to bovine serum 
albumin (BSA) via 2-iminothiolane and immobilized. The antibody 
was then incubated at 37 oC in the presence of this immobilized 
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FIG. 3. Coupling groups used in bifunctional chelates: isothiocyanatophenyl-
edta (1),  isothiocyanatophenyl-dtpa (2) [9]; PA-dota (3) [45]; polycarboxylate 
diazolylpyridine ligand derivatized with an isothiocyanato phenylcarbamoyl 
group (4) [46]; 4,4’-bis(heptafl uoro-4”,6”-hexanedion-6”-yl)chlorosulfo-o-
terphenyl (5, BHHCT) [10]; 1,10-bis(8’-chlorosulfo-dibenzothiophene-2’-yl)-
octafl uorodecane-1,3,8,10-tetraone (6, BCOT) [47]; p-aminosalicylate-dtpa (7, 
dtpa-pAS) [48]; methylphenanthridinium group for DNA intercalation 8 [49].
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complex and of a soluble metal complex with NBD. The antibody 
was found to bind all the lanthanide-NBD complexes, including the 
YIII and ScIII ones. A plot of the dependence of the standard Gibbs 
free energy on the metal ionic radius can be described by a parabola and 
points to elastic binding behavior between 2D12.5 and the rare earth-
NBD complexes. The dissociation constant for the Y-NBD complex is 
10–8 M and that of the most tightly bound GdIII complex is approximately 
three times smaller. Time-resolved luminescence shows an improved 
emission of the TbIII ion when bound to the antibody.
2.4. Methodological Aspects: Time-resolved Luminescence (TRS)
Measurement of the LnIII luminescence is fairly straightforward, 
although it requires a special instrumentation. First, a UV-light pulse 
is shined onto the sample (the wavelength is chosen via a special 
fi lter). Then a delay is applied, to let the background fl uorescence (and, 
possibly, short-lived phosphorescence) fade off, before starting light 
measurement (Figure 5). In this way, solely the LnIII luminescence is 
measured and signal-to-noise ratio is high. Moreover, the total length 
of the experiment is on the order of a few milliseconds, so that it can be 
repeated a few hundred times a second. In less than one minute, tens of 
thousand of measurements can be carried out, boosting even more the 
signal-to-noise ratio (which increases as the square root of the number 
of measurements). Sensitivities down to 10–13-10–15 M are easily 
reached.
FIG. 4. Formulae of two bifunctional dota-derivatives interacting with antibody 
2D12.5 [24].
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3. APPLICATIONS IN MEDICAL DIAGNOSIS
3.1. Heterogeneous versus Homogeneous Immunoassays
Most applications in medical diagnosis make use of immunoassays 
detected by time-resolved luminescence. At fi rst a two-step process was 
developed (Figure 6) in which a monoclonal antibody is linked to a 
europium chelate and let interact with the immobilized analyte (usually an 
hormone). After washing, the pH is lowered and the competition between 
protons and the metal ion releases the EuIII ion which is then complexed 
by a β-diketonate in order to trigger the antenna effect; to minimize water 
interaction, the new chelate is inserted into a micelle before time-resolved 
luminescence measurement.
The advantage of the homogeneous assays developed by Mathis [25] 
is their simplicity (Figure 7). The antigen to be analyzed is reacted with 
two specifi c monoclonal antibodies, one bearing a europium chelate and 
the other an energy acceptor emitting red light with high quantum yield. 
Following UV excitation of the EuIII chelate (or cryptate), energy is not 
emitted by the metal ion but, rather, transferred non-radiatively onto the 
acceptor which, in turn emits its characteristic fl uorescence. Since the 
excited state is populated by the de-excitation of the long-lived 5D0(Eu) 
level, red light is emitting with a lifetime characteristic of the latter, 
allowing TRS detection. The energy transfer occurs within distances 
characteristic of antigen-antibody complexes (7-10 nm), but not at greater 
FIG. 5. Principle of time-resolved luminescence.
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distances, which makes it quite specifi c. This type of assay can also detect 
protein-protein interaction and DNA hybridization.
3.2. Nucleic Acids and DNA Hybridization Probes
Advances in recombinant DNA technology and sensitive methods 
for analyzing the organization of specifi c genes are major contributors 
to genomics. These techniques rely on nucleic acid hybridization probes 
for the detection of complementary nucleic acid sequences. DNA probes 
are more and more used in diagnostic medicine, e.g., in the recognition of 
genetic predisposition to a given disease, virus detection, bacterial iden-
tifi cation or antibiotic sensitivity testing. Until the 1990’s, radioisotopes 
(e.g., 32P, 3H) were common labels for nucleic acid probes, but stability 
and safety problems led to search for alternative, non-isotopic stains. Truly 
biochemical methods were proposed, such as biotinylated nucleotide ana-
logues detected by streptavidin or proteins crosslinked to the nucleic acid, 
but their sensitivity never matched the sensitivity of radio-assays, leaving 
an opportunity for luminescent assays.
In one of the early tests, based on heterogeneous immunoassays, 
DNA probes (1.2 kb, single stranded) were chemically modifi ed with 
FIG. 6. Principle of a heterogeneous luminescent immunoassay. 
58 BÜNZLI LUMINESCENT LANTHANIDE PROBES AS TOOLS 59
immunogenic fl uorine (7-iodo-N-acetoxy-N-2-acetylaminofl uorene) 
or sulfone and, after hybridization, they were allowed to react with 
specifi c antibodies. The latter were, in turn, coupled to another antibody 
(anti-rabbit or anti-mouse IgG), labelled with a EuIII probe. In this way, 
adenovirus type 2 DNA could be quantifi ed in nasopharyngeal mucus, 
with a sensitivity of about 107 genomes per test [26].
Terbium-containing labels also proved to be highly sensitive in the 
detection of DNA fractions during polyacrylamide gel electrophoresis. 
The chelating ligand is prepared by reacting diethylenetriaminetetraace-
tic acid monoanhydride with p-aminosalicylate (acting as energy donor). 
It is then reacted with a plasmid digest, in the presence of terbium chlo-
ride, to yield a DNA-chelate conjugate, the luminescence of which is 
assessed quantitatively. The DNA-chelate conjugate is very stable, even 
at elevated temperature (60 oC) and in the presence of an electric fi eld 
[27]. Homogeneous essays have also been proposed, for instance by 
formation of ternary complexes with TbIII. In an earlier example, p-
aminosalicylate was attached to the 3’ end of an oligonucleotide while 
the 5’ end of another nucleotide was fi tted with a TbIII chelate with dtpa. 
The oligonucleotide sequences were chosen so that after hybridization, 
the energy donor and acceptor were positioned at an ideal distance for 
effi cient energy transfer. The sensitivity reached 1 picomole of template 
DNA per milliliter [28].
Detection of DNA hybridization (Figure 8) is made through reso-
nance energy transfer, according to a principle similar to that depicted in 
FIG. 7. Principle of a homogeneous luminescent immunoassay (Mab = 
monoclonal antibody).
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Figure 7 [29]. A europium chelate functionalized with a carbostyril-124 
dye (energy donor) is connected to the 5’ end of a single stranded DNA. 
Simultaneously, the 5’ end of the complementary single-stranded DNA is 
labelled with an energy acceptor (Cy-5, see Figure 8). When the two DNA 
strands interact, the EuIII ion and the acceptor are brought within suit-
able distance to allow a non-radiative energy transfer from the metal ion 
onto the organic dye. The sensitized emission of Cy-5 (having the same 
lifetime as EuIII) can be measured without interference from the (weak) 
remaining EuIII luminescence since it occurs at a different wavelength,
while its direct fl uorescence can be discriminated by time-resolved meas-
urement, ensuring high signal-to-noise ratio. A similar assay using TbIII 
luminescence and a rhodamine derivative as the energy acceptor has been 
described by the same authors.
3.3. Clinical Examples
A limited number of examples are described here, with the aim of 
showing the wide application range of the luminescence techniques for 
diagnosis purposes.
3.3.1. Human Immunoglobin IgE
The concentration of IgE is the lowest of the fi ve immunoglobins and 
is closely related to several allergies and analytical methods capable of 
FIG. 8. Luminescence detection of DNA hybridization. Redrawn after [29].
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measuring concentrations of IgE far lower than 100 pg/ml are needed. 
Competitive immunoradiometric assays reach a detection limit as low as 
40-300 pg/ml, but luminescence methods are much more sensitive. In the 
proposed assays [30], the authors use the BHHCT EuIII chelate (see Figure 
3) to label streptavidin (SA) and a bovine serum albumin-streptavidin 
conjugate (BSA-SA). A total of 21 and 46 molecules of the Eu-chelate 
can be bound to SA and BSA-SA, respectively. The entire analyses are 
performed with 96-well microtiter plates and solid-state luminescent 
measurements are performed. Calibration shows that analytical recovery 
is better than 87% and a sensitivity of 3.6 pg/ml is achieved with a 
reproducibility of 7%. The analysis time (4-5 h) is quite short compared to 
radioactive or enzymatic assays (several days).
3.3.2. α−Fetoprotein
Human α-fetoprotein (AFP) is one of the carcinoembryonic proteins 
and has been the subject of several analytical methods. Assays based 
on of time-resolved luminescence make use of the same Eu-chelate as 
previously, linked to streptavidin, SA-(BHHCT-Eu)21. The principle is 
depicted in Figure 9. The wells of a microtiter plate are coated with an 
anti AFP monoclonal antibody and the AFP solutions are added. After 
incubation, successive additions of an anti AFP antibody, a biotinylated 
anti IgG antibody, and of SA-(BHHCT-Eu)21 are each followed by 
incubation and thorough rinsing. The plate is subjected to solid-state 
luminescence measurement. Finally, the lanthanide label is liberated
into the solution and a second luminescence measurement is performed. 
The sensitivity attained is impressive, 4 × 10–15 g/ml, corresponding to 
an improvement of 4-5 orders of magnitude over the other analytical 
methods. The dynamic range of the method is also quite remarkable, with 
6 orders of magnitude (from 10–4 to 100 ng/ml). A similar method using 
the same chelating agent allows the simultaneous determination of AFP 
and carcinoembryonic antigen in human serum with detection limits of 
0.07 and 0.3 ng/ml, respectively [31].
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3.3.3. Herpes Simplex Virus
The herpes simplex virus (HSV) can be detected in the cerebrospinal 
fl uid, after amplifi cation by polymerase chain reactions (PCR). The bio-
tinylated PCR products are collected on streptavidin-coated microtitra-
tion wells and hybridiZed with short oligonucleotide probes containing 
a luminescent lanthanide ion: EuIII for HSV-1 and SmIII for HSV-2. This 
method proved to be very rapid and sensitive (down to 0.1 infectious 
unit) [32].
3.3.4. Prostate Specifi c Antigen
Target nucleic acids can be quantifi ed by direct hybridization assays 
but the high sensitivity needed in medical diagnosis often requires 
amplifi cation through PCR. The number of input template molecules 
is calculated from the amount of PCR product and quantifi cation is 
achieved by comparing the amplifi cation signal of the sample with the 
amplifi cation signal obtained from various amounts of a known stan-
dard. Homogeneous time-resolved luminescence detection is of great 
help in this type of analyses. In one example, Nurmi et al. propose both 
a competitive end-point and a real-time methods for the quantifi cation 
of prostate-specifi c antigen (PSA) double-stranded cDNA [33]. The 
FIG. 9. Principle of the α-fetoprotein assay (AFP; B = biotin; SA = streptavidin). 
Redrawn after [50].
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competitive assay makes use of a dual EuIII/TbIII label while the second 
method is based on a single TbIII label. Results obtained from the two 
assays are consistent. With respect to PSA, the relevant target amounts 
are between 102 and 106 molecules, while one prostate cancer cell con-
tains an average of 103 PSA mRNA molecules. If 30-40 PCR cycles are 
used, the sensitivity of the methods is around 10-50 input molecules of 
PSA cDNA. Lower detection limits can be achieved by increasing the 
number of PCR cycles.
3.3.5. Children Diabetes
In type 1 diabetes, progressive destruction of insulin-producing β-
cells occurs in the endocrine pancreas. Antibodies against β-cells can 
be detected in the serum of a prediabetic subject, indicating an ongoing 
autoimmune process before the diagnosis of the illness. Expression levels 
of mRNA specific for each cytokine have been determined in blood mono-
nuclear cells by multiple reverse transcription PCR followed by hybrid-
ization reactions with lanthanide-labeled probes detected by TRS. This 
study shows that children with newly diagnosed diabetes express smaller 
amounts of cytokines, compared to controls [34].
3.3.6. Determination of Grepafloxacin
Grepafloxacin is a drug administrated to patients with urinary, respira-
tory or cutaneous infections; it is a synthetic fluorinated quinolone deriva-
tive having activity against gram-positive and gram-negative bacteria. 
Callejón and co-workers have developed an analytical method based on 
the luminescence of the terbium-grepafloxacin complex to quantify its 
concentration in human urine and serum [35]. Average recoveries were 
around 90% and dynamic range between 10 and 500 ng/ml. It is notewor-
thy that this analysis is much simpler than the previously described ones 
in that terbium chloride is let to interact with the drug in the presence of 
sodium dodecylsulfate. The measurement technique (TRS) is, however, 
the same.
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3.4. Imaging Techniques for Enhanced Detection
 of Cancerous Cells
While magnetic resonance imaging (MRI) is a well established tool 
to monitor organs for carcinomas, in parallel there is a need for better 
methods for the in vivo analysis of specifi c tissues. Monitoring the fl uo-
rescence from the tissues is an appealing idea, but the signal is small and 
often diffi cult to interpret, henceforth the necessity for contrast enhancing 
agents, similarly to what is made in MRI. Metal chelates are candidates of 
choice. They must, however meet many stringent requirements, including 
high thermodynamic stability and suitable photophysical properties. With 
the knowledge acquired during the last decades, these requirements can 
be reasonably well fulfi lled, especially if lanthanide reporters are used, in 
view of their specifi c spectroscopic advantages (line-like emission in the 
visible, long lifetimes). 
A more diffi cult problem remains to be solved, namely, selectivity 
towards a specifi c tissue. One approach consisted in introducing exogenous 
markers similar to the drugs used in photodynamic therapy of cancer (see 
Section 4 below). These drugs, however, present a series of disadvantages, 
including their slow pharmacokinetics and light-induced toxicity. To date, 
the most promising approach has been pioneered by Bornhop et al. [36,37] 
who developed a class of terbium chelates with adequate properties from a 
cyclen framework fused with a pyridine ring. One of the chelating agents, 
termed PCTMB is depicted in Figure 10. The terbium chelate is very 
FIG. 10. Trianionic chelate (PCTMB) used in imaging of cancer cells.
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stable and, upon excitation in the UV (270 nm), emits a bright green light 
with a quantum yield of 51%. One drawback is UV excitation which may 
damage DNA, but the light intensity needed is low enough to be below the 
level inducing mutageneses. The neutral overall charge of the TbIII chelate 
and its lipophilic nature facilitate transport in tissues. Some selectivity has 
been observed as well, for instance an enhanced uptake of the chelate by 
abnormal colon tissue. Further tests of this compound are under way.
4. USE OF LANTHANIDE COMPLEXES
 IN PHOTODYNAMIC THERAPIES
Although not based on intrinsic lanthanide luminescence, remarkable 
properties of some lanthanide complexes are being used in photodynamic 
therapy of various pathologies, so that we briefly describe these emerging 
applications.
4.1. Principle of Photodynamic Therapy
In a rare blood disease, porphyria, porphyrins accumulate in the skin, 
bones and teeth. Although benign in the dark, porphyrins are transformed 
by sunlight into flesh-eating toxins. While trying to find a treatment to 
cure this disease, scientists realized that porphyrins could be a tool for 
medicine. Metal-free porphyrins, after excitation by absorption of light, 
can transfer their excess energy onto dioxygen to produce highly reac-
tive singlet oxygen, 1O2, or free radicals. These, in turn, destroy cells. 
Similarly, metalloporphyrins based on metals which do not interact with 
the extended delocalised π-system of the porphyrin ring, lead to the same 
effects. 
In fact, porphyrins possess another medically useful property: they 
accumulate in cancer cells, or more generally, in fast growing tissues, so 
that they are presently being explored in the context of a number of medi-
cal applications ranging from cancer therapy (the best known application), 
to cardiology, ophthalmology, or dermatology. Starting at the end of the 
1970’s, patients with breast, lung, prostate, and skin cancer have been 
treated by photodynamic therapy. In this cure, a porphyrin photosensitiser 
is administrated via intravenous injection and localizes in the cancerous 
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region. Visible (red) light is used to activate the sensitiser and to produce 
singlet oxygen, the cytotoxic agent. Results were encouraging, with 
almost 100% of complete or partial response. On the other hand, second-
ary effects developed, such as burns and skin rashes. Moreover, the early 
porphyrin treatments were seldom strong enough to kill the entire tumor. 
Finally, some porphyrins are activated by light that cannot penetrate deep 
enough in the tumor. Henceforth, the search for new porphyrins with a 
greater potency and which could be activated by light penetrating deeper 
in human tissues, in the near infrared range. One category of such photo-
sensitisers may be the texaphyrins.
4.2. Lanthanide Texaphyrins
At the end of the 1980’s, John Sessler from the University of Texas at 
Austin has developed a new class of pyrrole-based expanded porphyrins 
that he named “texaphyrins” (Figure 11) [38]. 
Like the porphyrins, texaphyrins are fully aromatic and highly 
colored. However, they form - formally - 22 π-electron systems instead 
of 18 π-electron ones; consequently, they are dark green rather than 
purple with their lowest energy transition falling at 700 nm instead of 
620 nm for porphyrins. Texaphyrins are monoionic ligands with a central 
core 20% larger than that of porphyrins and they are capable of binding 
a variety of metal cations, including lanthanide ions, and stabilizing a 
number of unusual coordination geometries. Due to their enlarged cavity 
with respect to porphyrins, they are ideally suited for forming very stable 
and highly inert complexes with lanthanide ions. The large stability of 
metallotexaphyrins is due to the ligand oxidation accompanying metal 
insertion; the macrocycle tightens up around the metal ion, preventing 
easy dissociation. Lanthanide complexes with several texaphyrin 
derivatives have been studied (R’ = H, R = CH3, OCH3, O(CH2)3OH for 
instance, see Figure 11). The structure of the gadolinium complex with the 
texaphyrin HTex1 contains cationic species [Gd(NO3)(MeOH)2(Tex1)]+ 
with a nine-coordinate metal ion (Figure 12); the Gd(III) ion is ligated 
by the fi ve nitrogen atoms of the ligand, one bidentate nitrate ion and two 
molecules of methanol; it sits at approximately 0.6 Å from the plane of the 
fi ve nitrogen atoms.
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Lanthanide complexes with texaphyrins are easier to reduce than typical 
metalloporphyrins. For example, the following potentials have been mea-
sured versus normal hydrogen electrode in dmf: E1/2 = –0.041 and –0.044 
V for Gd and La complexes with HTex2 (Figure 13) as compared to –1.41 
V for a Zn(II) octaethylporphyrinate. This fact, coupled with the observa-
tion that texaphyrins show the tumour selectivity characteristics of many 
porphyrins, led to testing GdTex2 as an enhancing agent in X-ray radiation 
therapy. In addition, the GdTex2 complex presents a sizable relaxivity so 
that it is detectable by magnetic resonance imaging techniques, allowing 
non-invasive evaluation of its localization in tissues (and, of course of its 
elimination from tissues). It has been demonstrated that this agent works 
particularly well in vivo and clinical tests are under way.
Another complex of Tex2 has interesting applications, LuTex2: (i) its 
Q-type absorption band occurs at 720 nm, a wavelength at which most of 
the body tissues are transparent, (ii) the yield of the intersystem crossing 
process is high, and (iii) so is the yield of singlet oxygen production (up 
to 70% depending on the exact experimental conditions) [39]. Addition-
ally, it has other advantages over the previous sensitizers, being a well 
defi ned, water-soluble compound, which renders its administration easy. 
Finally, its toxicity in absence of light is low, refl ecting a rapid clearance 
from the tissues. This compound is present in several drugs used in dif-
ferent therapies.
FIG. 11. Oxidative formation of a lanthanide texaphyrin complex.
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4.3. Clinical Applications
4.3.1. Cancer Phototherapy
The lutetium complex with Tex2 is developed for oncologic appli-
cations under the trade name LUTRIN® by Pharmacyclics Inc. A study 
(phase I human clinical trial) was completed in 1997 on 35 patients with 
incurable cutaneous malignancies, including 15 recurrent breast cancers. 
After intravenous injection of the photosensitizer, they were irradiated by 
732-nm light. Out of the 176 lesions examined, 28% regressed completely 
FIG. 12. Structure of [Gd(NO3)(MeOH)2(Tex1)]+, redrawn from [51].
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and 20% partially (i.e., decreasing in size by at least 50%). The response 
was quite better for recurrent breast cancers (45% and 18%, respectively), 
so that a phase II clinical trial, completed in 1999, concerned solely patients 
with locally recurrent breast cancer. Tumor response was observed in 62% 
of the 52 patients involved. Assessment following treatment indicated that 
the lesions were no more detectable in 20% of the cases while 22% had 
undergone sizeable reductions [38,40].
The chest wall has a large area (240 cm2) and several parameters have 
to be adjusted carefully, which, in parallel with clinical trials, generates 
a wealth of preclinical developments, both with respect to the irradiation 
conditions [41], to the elucidation of the mechanism of action of LUTRIN® 
[42], and to the understanding of its biolocalization properties.
4.3.2. Photoangioplasty
A few years ago, Woodburn and coworkers explored the possibility 
of using a lutetium complex with texaphyrin Tex2 (under the trade name 
ANTRIN®) in the removal of atheromatous plaque [43]. Atherosclerotic 
vascular disease is indeed one of the leading cause of death in the West-
ern world. The fact that porphyrin-like macrocycles are taken up more in 
FIG. 13. Developed formula of HTex2.
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atheromatous plaque than in the walls of normal vessels motivated this 
development. In a phase I clinical trial, the drug was administrated intra-
venously; then a 24-h delay was applied in order to maximize the uptake 
of ANTRIN® in the plaque, while maximizing the clearance from plasma. 
Finally, 732-nm light was shined through an intravascular fiberoptic cath-
eter. The trial revealed a safe, well-tolerated  treatment without adverse vas-
cular responses for patients with non-critical arteriosclerosis; in particular, 
one patient showed a nearly 50% improvement in luminal diameter [38,40]. 
Presently, Woodburn envisages extension of this therapy to graft coronary 
artery disease which limits patient survival following heart transplantation.
4.3.3. Age-Related Macular Degeneration
Almost one quarter of the people over the age of 65 suffer from 
macular degeneration, which is the major cause of blindness in the elderly 
people, particularly its wet form. Another form of Lu(Tex2), OPTRIN® is 
in phase II clinical trial for treating this disease, after a successful preclini-
cal test on New Zealand white rabbits [44]. The clinical study points to 
the texaphyrin drug localizing selectively in the choroidal neovasculariza-
tion. Depending on the dose of drug and light, as well as on the interval 
between them, complete or partial closure of diseased vessels is achieved. 
In a preliminary analysis of the patients with complete or partial closure, 
visual acuity was found to increase substantially.
5. CONCLUDING REMARK
In this short review, the emphasis was put on the basic principles 
pertaining to the design of efficient luminescent lanthanide-containing 
labels for medical diagnosis and therapy. Various applications have been 
mentioned which demonstrate that the unique spectroscopic properties of 
the lanthanide ions, coupled with their peculiar chemical properties, can 
be taken advantage of to develop extremely sensitive analytical meth-
ods in the field of biology, medicine and pharmacy. These methods are 
already largely in use in most hospitals and associated laboratories. Their 
sensitivity being better compared to analytical methods based on radio-
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active labels, there is no doubt that they are promised to a bright future, 
especially with the growing interest for genomics and high throughput 
screening. Their applications seem only limited by the imagination of 
the scientists and medical doctors. On a more historical viewpoint, it is 
amusing that the initial thrust for the development of time-resolved lumi-
nescence analyses for biomedical purposes and based on lanthanide-con-
taining labels came from the very university (Turku, Finland) where Johan 
Gadolin discovered the first rare-earth element, yttrium, in 1794 (at that 
time the city was Swedish-ruled and named Åbo).
ACKNOWLEDGMENT
The author is indebted to the Swiss National Science Foundation and 
the Swiss Federal Office for Education and Science (COST Action D18: 








BSA bovine serum albumin







HSV herpes simplex virus
Ig immunoglobulin
72 BÜNZLI LUMINESCENT LANTHANIDE PROBES AS TOOLS 73
LMCT ligand-to-metal charge transfer
LRET luminescent resonant energy transfer
Mab monoclonal antibody
MLCT metal-to-ligand charge transfer
MRI magnetic resonance imaging
NBD (S)-2-(4-nitrobenzyl)
pAS p-aminosalicylate
PCR polymerase chain reaction
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